Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: A nationwide cohort study

Circulation

Volumn 126, Issue 16, 2012, Pages 1955-1963

  Olsen, Anne Marie Schjerning ^a   Fosbøl, Emil L ^a,c   Lindhardsen, Jesper ^a   Folke, Fredrik ^a   Charlot, Mette ^a   Selmer, Christian ^a   Bjerring Olesen, Jonas ^a   Lamberts, Morten ^a   Ruwald, Martin H ^a   Køber, Lars ^b   Hansen, Peter R ^a   Torp Pedersen, Christian ^a   Gislason, Gunnar H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

mortality; myocardial infarction; nonsteroidal anti inflammatory drugs selective cyclooxygenase 2 inhibitors; prognosis

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DENMARK; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COHORT STUDIES; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DENMARK; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHARMACY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS;

EID: 84867519993     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.112607     Document Type: Article

References (34)

1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115: 1634-1642. (Pubitemid 46648649)
2. Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, Torp-Pedersen C, Gislason GH. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123:2226-2235.
3. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46:263-268.
4. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997; 44:445-448. (Pubitemid 27382061)
5. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003; 56:124-130. (Pubitemid 36315938)
6. Gislason GH, Abildstrom SZ, Rasmussen JN, Rasmussen S, Buch P, Gustafsson I, Friberg J, Gadsboll N, Kober L, Stender S, Madsen M, Torp-Pedersen C. Nationwide trends in the prescription of beta-blockers and angiotensin- converting enzyme inhibitors after myocardial infarction in Denmark, 1995-2002. Scand Cardiovasc J. 2005; 39:42-49. (Pubitemid 40662735)
7. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008; 117:1945-1954. (Pubitemid 351543470)
8. Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiol Drug Saf. 2008; 17:822-833.
9. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006; 113:2906-2913. (Pubitemid 44297231)
10. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol. 2001; 37:992-997. (Pubitemid 32217595)
11. Rasmussen S, Zwisler AD, Abildstrom SZ, Madsen JK, Madsen M. Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care. 2005; 43:970-978. (Pubitemid 41442462)
12. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, Van de Werf F, Pieper K, Califf RM, Pfeffer MA. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005; 352: 2581-2588. (Pubitemid 41007844)
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343:1520-1528, 1522 p following 1528.
14. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352:1092-1102. (Pubitemid 40365350)
15. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352:1071-1080. (Pubitemid 40365348)
16. Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide casecontrol study from Finland. Eur Heart J. 2006; 27:1657-1663. (Pubitemid 44025350)
17. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296:1633-1644. (Pubitemid 44511610)
18. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332:1302-1308.
19. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (medal) programme: a randomised comparison. Lancet. 2006; 368:1771-1781. (Pubitemid 44739003)
20. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364:2021-2029. (Pubitemid 39593078)
21. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004; 363:1751-1756. (Pubitemid 38698377)
22. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med. 2002; 162:1099-1104. (Pubitemid 34522394)
23. Strand V. Are cox-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370:2138-2151. (Pubitemid 350296305)
24. Recess! Diagnostics! http://www.medstat.dk. Accessed May 29, 2012.
25. Fosbol EL, Folke F, Jacobsen S, Rasmussen JN, Sorensen R, Schramm TK, Andersen SS, Rasmussen S, Poulsen HE, Kober L, Torp-Pedersen C, Gislason GH. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010; 3:395-405.
26. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med. 2002; 162:1111-1115. (Pubitemid 34522396)
27. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002; 162:1105-1110. (Pubitemid 34522395)
28. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin k antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374:1967-1974.
29. Ray WA. Cardiovascular safety of NSAIDs. BMJ. 2011; 342:c6618.
30. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011; 342:c7086.
31. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107:1303-1307. (Pubitemid 36314415)
32. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation. 2004; 110:1774-1779. (Pubitemid 39299220)
33. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "highgrade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003; 108:2957-2963. (Pubitemid 37553561)
34. Madsen JK, Grande P, Saunamaki K, Thayssen P, Kassis E, Eriksen U, Rasmussen K, Haunso S, Nielsen TT, Haghfelt T, Fritz-Hansen P, Hjelms E, Paulsen PK, Alstrup P, Arendrup H, Niebuhr-Jorgensen U, Andersen LI. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation. 1997; 96:748-755. (Pubitemid 27329605)